Here are the 10-K annual reports from NeoGenomics, Inc. (NEO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow NEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NEO filings page.
NeoGenomics, Inc. is an oncology-focused diagnostics company that runs CAP-accredited and CLIA-certified labs across the U.S. and an ISO-certified lab in Cambridge, U.K. It offers cytogenetics, FISH, flow cytometry, IHC, molecular and NGS panels, MRD testing, morphologic analysis, pharma trial support, and oncology data solutions.
The company serves community oncologists, pathologists, hospitals, reference labs, academic centers, and pharmaceutical sponsors through a single operating segment. Key 2026 priorities include expanding therapy selection and MRD products, deepening its community oncology footprint, improving automation and customer experience, and strengthening culture and cross-functional collaboration.
NeoGenomics operates in a rapidly evolving precision oncology market with growing demand for predictive and MRD testing, but faces intense competition, significant regulatory oversight, reimbursement pressure, data privacy obligations, and operational risks outlined in extensive risk factors.